Flexible Stenting Solutions, Inc. Announces IDE Submission for FlexStent(R) Femoropopliteal Self Expanding Stent System

EATONTOWN, N.J.--(HSMN NewsFeed)--Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial stents has submitted an Investigational Device Exemption (IDE) application to the FDA for its FlexStent(R) Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries. This next generation femoropopliteal stent and delivery system can significantly improve patient care in the high growth peripheral vascular segment.

While stent procedures have become widespread in the treatment of coronary arterial disease, their use in the more challenging peripheral vascular disease setting had been limited in the last several years by inadequate stent design. The fully connected flexible FlexStent(R) has coupled technology with clinical needs by providing a highly durable and fatigue resistant stent. The FlexStent(R) has superior radial stiffness, as well as excellent conformability to and mobility with the treated vessel. The delivery system provides simplicity, ease-of-use and accurate, uniform stent placement for the vascular interventionalist.

Full text >>